Key result
ELRA, IVC reconstruction, and PRaG therapy achieve 2-year partial disease control in unresectable IVC leiomyosarcoma.
Why the study?
Primary inferior vena cava leiomyosarcoma presents unique diagnostic and treatment challenges due to its rarity and lack of consensus on surgical and adjuvant approaches.
Does multidisciplinary management including ELRA, IVC reconstruction, and PRaG therapy improve outcomes in a patient with primary IVC leiomyosarcoma?
Case Report (n=1)
Does multidisciplinary management including ELRA, IVC reconstruction, and PRaG therapy improve outcomes in a patient with primary IVC leiomyosarcoma?
Multidisciplinary management including ELRA, IVC reconstruction, and PRaG therapy may offer a feasible approach for unresectable primary IVC leiomyosarcoma, though recurrence remains a significant challenge.
Case of primary IVC leiomyosarcoma adds to sparse literature; leaves optimal surgical and adjuvant strategies unresolved.
Introduction: Primary Inferior vena cava (IVC) leiomyosarcoma, a rare malignant tumor, presents unique challenges in diagnosis and treatment due to its rarity and the lack of consensus on surgical and adjuvant therapy approaches. Case Report: A 39-year-old female patient presented with lower limb swelling and mild fatigue. Contrast-enhanced CT identified a tumor mass within the dilated IVC. Abdominal MRI revealed primary IVC leiomyosarcoma extending into the right hepatic vein. A multidisciplinary consultation established a diagnosis and devised a treatment plan, opting for Ex-vivo Liver Resection and Auto-transplantation (ELRA), tumor resection and IVC reconstruction. Pathological examination confirmed primary IVC leiomyosarcoma. Postoperatively, the patient underwent a comprehensive treatment strategy that included radiochemotherapy, immunotherapy, targeted therapy, and PRaG therapy (PD-1 inhibitor, Radiotherapy, and Granulocyte-macrophage colony-stimulating factor). Despite the tumor's recurrence and metastasis, the disease progression was partially controlled. Conclusion: This case report emphasizes the complexities of diagnosing and treating IVC leiomyosarcoma and highlights the potential benefits of employing ELRA, IVC reconstruction, and PRaG therapy. Our study may serve as a valuable reference for future investigations addressing the management of this rare disease.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) conducted a case report in Primary inferior vena cava leiomyosarcoma (n=1). Ex-vivo Liver Resection and Auto-transplantation (ELRA), IVC reconstruction, and PRaG therapy was evaluated on Disease progression and survival. A multidisciplinary approach including ELRA, IVC reconstruction, and PRaG therapy achieved partial disease control at 2 years post-surgery in a patient with primary unresectable IVC leiomyosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: